Literature DB >> 31130326

Gaucher disease type 3c: New patients with unique presentations and review of the literature.

Alina Kurolap1, Mireia Del Toro2, Ronen Spiegel3, Ariel Gutstein4, Gideon Shafir5, Ian J Cohen6, José A Barrabés7, Hagit Baris Feldman8.   

Abstract

Gaucher disease (GD) is the most prevalent lysosomal disorder caused by GBA mutations and abnormal glucocerebrosidase function, leading to glucocerebrosideaccumulation mainly in the liver, spleen, bone marrow, lungs, and occasionally in the central nervous system. Gaucher disease type 3c (GD3c) is a rare subtype of the subacute/chronic neuronopathic GD3, caused by homozygosity for the GBA p.Asp448His (D409H) mutation. GD3c is characterized mainly by cardiovascular and neuro-ophthalmological findings. In this paper, we describe four new GD3c patients exhibiting rare cardiovascular, pulmonary and psychiatric findings, as well as atypical disease courses. Review of the GD3c-related literature revealed clinical descriptions of 36 patients, presenting predominantly with cardiovascular calcifications; 15%, including Patient 1b in this study, had non-calcified lesions - fibrosis and atherosclerosis. Only 7.5% of patients have been described without heart disease, including Patient 3; however, Patient 2 had a fulminant coronary disease. Neurological findings in GD3c consist mainly of oculomotor apraxia (80%), which is absent in Patient 3, while other neurological findings are common (65%) but diverse. Patient 1b developed a psychiatric behavioral disorder, which has not been previously described in GD3c. Patient 1b also had interstitial lung disease, which was only described in one GD3c patient as pulmonary fibrosis. In view of these unique features, we recommend a revised surveillance protocol; however, further studies are required to establish the management of these patients and the role of GBA in the described pathologies.
Copyright © 2019 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Coronary artery stenosis; D409H; GD3c; Gaucher disease type 3c; Interstitial lung disease; p.Asp448His

Mesh:

Substances:

Year:  2019        PMID: 31130326     DOI: 10.1016/j.ymgme.2019.05.011

Source DB:  PubMed          Journal:  Mol Genet Metab        ISSN: 1096-7192            Impact factor:   4.797


  5 in total

1.  Allogeneic hematopoietic stem cell transplantation for treating severe lung involvement in Gaucher disease.

Authors:  Fu-Shiuan Lee; Hsiu-Ju Yen; Dau-Ming Niu; Giun-Yi Hung; Chih-Ying Lee; Yi-Chen Yeh; Paul Chih-Hsueh Chen; Sheng-Kai Chang; Chia-Feng Yang
Journal:  Mol Genet Metab Rep       Date:  2020-10-20

Review 2.  Diagnosing neuronopathic Gaucher disease: New considerations and challenges in assigning Gaucher phenotypes.

Authors:  Emily C Daykin; Emory Ryan; Ellen Sidransky
Journal:  Mol Genet Metab       Date:  2021-01-09       Impact factor: 4.797

3.  Increased Alveolar Heparan Sulphate and Reduced Pulmonary Surfactant Amount and Function in the Mucopolysaccharidosis IIIA Mouse.

Authors:  Tamara L Paget; Emma J Parkinson-Lawrence; Paul J Trim; Chiara Autilio; Madhuriben H Panchal; Grielof Koster; Mercedes Echaide; Marten F Snel; Anthony D Postle; Janna L Morrison; Jésus Pérez-Gil; Sandra Orgeig
Journal:  Cells       Date:  2021-04-08       Impact factor: 6.600

Review 4.  Clinical and biochemical footprints of inherited metabolic diseases. IV. Metabolic cardiovascular disease.

Authors:  Carlos R Ferreira; Nenad Blau
Journal:  Mol Genet Metab       Date:  2020-12-25       Impact factor: 4.797

5.  Cardiac Manifestations in a Group of Romanian Patients with Gaucher Disease Type 1 (a Monocentric Study).

Authors:  Cecilia Lazea; Simona Bucerzan; Camelia Al-Khzouz; Anca Zimmermann; Ștefan Cristian Vesa; Ioana Nașcu; Victoria Creț; Mirela Crișan; Carmen Asăvoaie; Diana Miclea; Paula Grigorescu-Sido
Journal:  Diagnostics (Basel)       Date:  2021-05-29
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.